Anti-Human FOLH1/PSMA & CD3E Bispecific Reference Antibody (Pasotuxizumab, RUO)

Description: Pasotuxizumab (BS10400) is a research-grade recombinant antibody targeting CD3. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: (scFv-heavy-kappa)-(scFv-heavy-lambda)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: NAALAD1,Prostate-specificmembraneantigen,NAALADaseI,PSMA,PSM,Pteroylpoly-gamma-glutamatecarboxypeptidase,Glutamatecarboxypeptidase2,N-acetylated-alpha-linkedacidicdipeptidaseI,GlutamatecarboxypeptidaseII,FOLH1,FGCP,FOLH,Folylpoly-gamma-glutamatecarboxypeptidase,Folatehydrolase1,GCPII,Membraneglutamatecarboxypeptidase,Cellgrowth-inhibitinggene27protein,mGCP,T3E,T-cellsurfaceantigenT3/Leu-4epsilonchain,CD3e,CD3E,T-cellsurfaceglycoproteinCD3epsilonchain
Purification: Purified by Nickel column.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,BAY2010112,BITEMT112,MT-112,CAS:1442657-12-6
Background: Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.
Note: For research use only. Not suitable for clinical or therapeutic use.